At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
Lenalidomide +1 moredrug
Likely dose
Lenalidomide 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Lenalidomide (CC-5013) and Prednisone as a Therapy for Patients With Myelofibrosis (MF)
In Brief
A Phase 2 clinical trial evaluating Lenalidomide and Prednisone for Myelofibrosis. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn if lenalidomide in combination with prednisone can help to control myelofibrosis. The safety of lenalidomide and prednisone for the treatment of myelofibrosis will also be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyelofibrosis
CountriesUnited States
CollaboratorsCelgene Corporation
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2006
First PostedJul 2006
Primary CompletionMar 2018
TodayJul 2026
First PostedJul 17, 2006
Enrollment StartJul 7, 2006
Primary CompletionMar 8, 2018
TodayJul 2, 2026
Enrollment to primary: 11.7 yearsPosted 20.0 years ago
Interventions
Lenalidomidedrug
Oral 10 mg daily/days 1-21 of 28 day cycle
Prednisonedrug
Starting dose oral 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.